ResApp field-tests health app in the developing world

Company News

by David Chau

Digital health company, ResApp Health Ltd (ASX:RAP), is developing smartphone apps which diagnose and manage respiratory diseases – including pneumonia, asthma and bronchitis.

The company says it has shipped smartphones to a “leading global humanitarian organisation” for the purpose of field-testing its diagnostic app. ResApp has not revealed who this humanitarian organisation is just yet.

ResApp says the field evaluation is a precursor to a large-scale multi country study of the system’s ability to diagnose respiratory disease.

ResApp says this field trial will generate additional clinical evidence, and garner an in-depth understanding of the local conditions so that the company can optimise a product for essential medical personnel working in very challenging environments.

ResApp reported a net loss of $3.2 million at 30 June 2016.

David Chau

Finance News Network
David joined FNN in April 2016. In addition to presenting the Market Outlook and latest business news stories, David interviews senior economists and CEOs of ASX-listed companies. Prior to working for FNN, David was a litigation lawyer.